RYBRILA

This brand name is authorized in Finland, Ireland.

Active ingredients

The drug RYBRILA contains one active pharmaceutical ingredient (API):

1	Glycopyrronium UNII V92SO9WP2I - GLYCOPYRROLATE
	Glycopyrronium is an inhaled long-acting muscarinic receptor antagonist (anticholinergic) for once-daily maintenance bronchodilator treatment of COPD. Glycopyrronium works by blocking the bronchoconstrictor action of acetylcholine on airway smooth muscle cells, thereby dilating the airways.
	Read more about Glycopyrronium

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
RYBRILA Oral solution	MPI, EU: SmPC	Health Products Regulatory Authority (IE)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A03AB02	Glycopyrronium bromide	A Alimentary tract and metabolism → A03 Drugs for functional gastrointestinal disorders → A03A DRUGS FOR FUNCTIONAL BOWEL DISORDERS → A03AB Synthetic anticholinergics, quaternary ammonium compounds
Discover more medicines within A03AB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
FI	Lääkealan turvallisuus- ja kehittämiskeskus	059572